Avadel Pharmaceuticals (Avadel Pharmaceuticals) Interest Expense : $-9.89 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Avadel Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -2.35 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.89 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Avadel Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -24.90 Mil. Avadel Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -2.35 Mil. Avadel Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avadel Pharmaceuticals Interest Expense Historical Data

The historical data trend for Avadel Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Interest Expense Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-12.48

-12.99

-9.94

-12.34

-9.89

Avadel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-3.26	-3.26	-2.30	-1.98	-2.35

Avadel Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.89 Mil.

Avadel Pharmaceuticals (NAS:AVDL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avadel Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-2.35 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-24.90 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1.69 Mil.

Avadel Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Avadel Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AWK1:Germany AWK1:Germany

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Executives

Thomas S Mchugh	officer: Chief Financial Officer	2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Geoffrey Michael Glass	director	4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Richard J Kim	officer: Chief Commercial Officer	16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Linda Palczuk	director	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Peter Thornton	director	TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Douglas J Williamson	officer: Chief Medical Officer	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn	officer: Sr. VP, Technical Operations	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow	officer: Chief Medical Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15